{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:37:11Z","timestamp":1784029031865,"version":"3.55.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C355\/A25137"],"award-info":[{"award-number":["C355\/A25137"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000362","name":"Asthma and Lung UK","doi-asserted-by":"publisher","award":["MESO15-12"],"award-info":[{"award-number":["MESO15-12"]}],"id":[{"id":"10.13039\/501100000362","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000351","name":"British Lung Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.isci.2024.111525","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T02:39:33Z","timestamp":1733107173000},"page":"111525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma"],"prefix":"10.1016","volume":"28","author":[{"given":"Josephine","family":"Carpentier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valle","family":"Morales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiuscia","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Bomalaski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Szlosarek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3321-6601","authenticated-orcid":false,"given":"Sarah A.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2024.111525_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2024.111525_bib2","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial","volume":"402","author":"Chu","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2024.111525_bib3","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1002\/ijc.25202","article-title":"Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer","volume":"126","author":"Delage","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2024.111525_bib4","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In\u00a0vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2024.111525_bib5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaoncol.2016.3049","article-title":"Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial","volume":"3","author":"Szlosarek","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2024.111525_bib6","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.isci.2024.111525_bib7","doi-asserted-by":"crossref","first-page":"CT007","DOI":"10.1158\/1538-7445.AM2023-CT007","article-title":"Abstract CT007: Phase 2-3 trial of pegargiminase plus chemotherapy versus placebo plus chemotherapy in patients with non-epithelioid pleural mesothelioma","volume":"83","author":"Szlosarek","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2024.111525_bib8","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jamaoncol.2023.6789","article-title":"Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial","volume":"10","author":"Szlosarek","year":"2024","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2024.111525_bib10","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2174\/138161208784246199","article-title":"Arginine deprivation as a targeted therapy for cancer","volume":"14","author":"Feun","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.isci.2024.111525_bib11","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s43440-023-00480-6","article-title":"A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma","volume":"75","author":"Phillips","year":"2023","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.isci.2024.111525_bib12","first-page":"78","article-title":"Arginine deprivation in cancer therapy","volume":"18","author":"Feun","year":"2015","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"10.1016\/j.isci.2024.111525_bib13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1038\/s41568-018-0054-z","article-title":"Rewiring urea cycle metabolism in cancer to support anabolism","volume":"18","author":"Keshet","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.isci.2024.111525_bib9","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1158\/0008-5472.CAN-08-3157","article-title":"Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis","volume":"69","author":"Kim","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.isci.2024.111525_bib14","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1158\/1078-0432.CCR-22-2642","article-title":"Discovery and targeting of a noncanonical mechanism of sarcoma resistance to ADI-PEG20 mediated by the microenvironment","volume":"29","author":"Rogers","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2024.111525_bib15","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.celrep.2016.06.097","article-title":"Inhibition of the Polyamine Synthesis Pathway Is Synthetically Lethal with Loss of Argininosuccinate Synthase 1","volume":"16","author":"Locke","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.isci.2024.111525_bib17","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.cmet.2019.05.003","article-title":"Polyamines and eIF5A Hypusination Modulate Mitochondrial Respiration and Macrophage Activation","volume":"30","author":"Puleston","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.isci.2024.111525_bib18","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/0271678X20928882","article-title":"Inhibition of eIF5A hypusination pathway as a new pharmacological target for stroke therapy","volume":"41","author":"Bourourou","year":"2021","journal-title":"J.\u00a0Cereb. Blood Flow Metab."},{"key":"10.1016\/j.isci.2024.111525_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010152","article-title":"Akt Inhibition as Preconditioning Treatment to Protect Kidney Cells against Anoxia","volume":"23","author":"Melis","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2024.111525_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1681\/ASN.2016010012","article-title":"Targeting eIF5A Hypusination Prevents Anoxic Cell Death through Mitochondrial Silencing and Improves Kidney Transplant Outcome","volume":"28","author":"Melis","year":"2017","journal-title":"J.\u00a0Am. Soc. Nephrol."},{"key":"10.1016\/j.isci.2024.111525_bib21","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/s41598-018-38341-5","article-title":"eIF5A inhibition influences T\u00a0cell dynamics in the pancreatic microenvironment of the humanized mouse model of Type 1 Diabetes","volume":"9","author":"Imam","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2024.111525_bib22","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s00726-016-2275-3","article-title":"Targeting the polyamine-hypusine circuit for the prevention and treatment of cancer","volume":"48","author":"Nakanishi","year":"2016","journal-title":"Amino Acids"},{"key":"10.1016\/j.isci.2024.111525_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043468","article-title":"Expression of eukaryotic initiation factor 5A and hypusine forming enzymes in glioblastoma patient samples: implications for new targeted therapies","volume":"7","author":"Preukschas","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2024.111525_bib24","doi-asserted-by":"crossref","first-page":"5304","DOI":"10.1038\/onc.2016.71","article-title":"The hypusine cascade promotes cancer progression and metastasis through the regulation of RhoA in squamous cell carcinoma","volume":"35","author":"Muramatsu","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.isci.2024.111525_bib25","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13402-014-0201-9","article-title":"Deoxyhypusine synthase (DHPS) inhibitor GC7 induces p21\/Rb-mediated inhibition of tumor cell growth and DHPS expression correlates with poor prognosis in neuroblastoma patients","volume":"37","author":"Bandino","year":"2014","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.isci.2024.111525_bib26","first-page":"1283","article-title":"GC7 enhances cisplatin sensitivity via STAT3 signaling pathway inhibition and eIF5A2 inactivation in mesenchymal phenotype oral cancer cells","volume":"39","author":"Fang","year":"2018","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.isci.2024.111525_bib27","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41419-020-03174-6","article-title":"Blockade of EIF5A hypusination limits colorectal cancer growth by inhibiting MYC elongation","volume":"11","author":"Coni","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2024.111525_bib28","first-page":"2608","article-title":"GC7 blocks epithelial-mesenchymal transition and reverses hypoxia-induced chemotherapy resistance in hepatocellular carcinoma cells","volume":"9","author":"Zhou","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.isci.2024.111525_bib29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1002\/ijc.25100","article-title":"Prognostic significance and therapeutic potential of eukaryotic translation initiation factor 5A (eIF5A) in hepatocellular carcinoma","volume":"127","author":"Lee","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.isci.2024.111525_bib30","doi-asserted-by":"crossref","first-page":"12474","DOI":"10.1074\/jbc.M110.106419","article-title":"The role of polyamines in supporting growth of mammalian cells is mediated through their requirement for translation initiation and elongation","volume":"285","author":"Landau","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.isci.2024.111525_bib31","doi-asserted-by":"crossref","first-page":"24348","DOI":"10.18632\/oncotarget.8324","article-title":"Eukaryotic translation initiation factor 5A2 regulates the migration and invasion of hepatocellular carcinoma cells via pathways involving reactive oxygen species","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2024.111525_bib32","doi-asserted-by":"crossref","first-page":"82658","DOI":"10.18632\/oncotarget.12308","article-title":"Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1alpha, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation","volume":"7","author":"Long","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.isci.2024.111525_bib16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/bs.mie.2015.05.016","article-title":"Analysis of Cell Metabolism Using LC-MS and Isotope Tracers","volume":"561","author":"Mackay","year":"2015","journal-title":"Methods Enzymol."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224027524?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004224027524?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:23:35Z","timestamp":1761438215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004224027524"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S2589004224027524"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2024.111525","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overcoming resistance to arginine deprivation therapy using GC7 in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2024.111525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111525"}}